Photochemotherapy and Graft-versus-leukemia in Acute-leukemia

CompletedOBSERVATIONAL
Enrollment

47

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions
ALLAMLAcute GVHDTumor Immunity
Interventions
RADIATION

Photochemotherapy

Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320-400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2-1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3-5 times each week.

Trial Locations (1)

14186

Department of Dermatology, Karolinska University Hospital Huddinge, Stockholm

All Listed Sponsors
lead

Karolinska University Hospital

OTHER

NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia | Biotech Hunter | Biotech Hunter